SLC5A2 and chronic kidney disease: A comprehensive meta-analysis assessing the cardioprotective properties of SGLT2 inhibitors in individuals with CKD stages 3 and 4 indicated a 26% decrease in the risk of CV mortality and HHF, with particularly significant reductions observed in the CKD stage 3a (30%) and stage 3b (23%) subgroups [65].